Bloss.

Trial name or title	Combination chemotherapy compared with hormone therapy in treating patients with recurrent, stage III or stage IV endometrial cancer
Methods	Randomised phase III trial
Participants	Patients with recurrent, stage III, or stage IV endometrial cancer
Interventions	Biological: filgrastim Drug: cisplatin Drug: megestrol acetate Drug: paclitaxel Drug: tamoxifen citrate
Outcomes	Progression‐free survival Response Determine if progesterone status provides information on whether patients are more likely to benefit from chemotherapy Toxicity profiles Quality of life
Starting date	May 2001
Contact information	Jeffrey D. Bloss, MD, Study Chair, Siteman Cancer Center at Barnes‐Jewish Hospital ‐ Saint Louis
Notes	Study completed ‐ no published results yet. Preliminary results regarding survival requested from the Study Chair.